Pharma tariff threat tests Roche US investment ambitions
Select your language
Generated with artificial intelligence.
Listening:
Pharma tariff threat tests Roche US investment ambitions
Swiss pharmaceutical firm Roche could reconsider investing billions of dollars in the United States after President Donald Trump's pledge to lower medication costs.
+Get the most important news from Switzerland in your inbox
Roche and Novartis have both recently announced huge US investments, partly in the hope of gaining goodwill from Trump’s administration. But the US is now targeting substantial price reductions on medications.
+ Trump tariffs put pressure on Swiss pharma
“If the proposed executive order goes into effect, the significant investments in the US we previously announced would be put to the test,” said a Roche spokesperson, confirming a report in the Neue Zürcher Zeitung.
A little over a month ago, Novartis announced it would invest $23 billion in additional factories and research laboratories in the US over the next five years. Roche plans to spend $50 billion on capacity expansion over the same period.
Trump’s executive order has instructed the US Department of Health and Human Services to begin negotiations with pharmaceutical companies within the next 180 days.
The department is expected to compile a list of benchmark prices within the next 30 days. If the manufacturers don’t lower the prices themselves, the Trump administration will attempt to do so through legislation.
More
Trump’s promise to lower drug prices rattles Swiss pharma stocks
Translated from German by DeepL/mga
How we work
We select the most relevant news for an international audience and use automatic translation tools such as DeepL to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication. Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
Did you find this explanation helpful? Please fill out the short survey below to help us understand your needs.
External Content
In compliance with the JTI standards
More: SWI swissinfo.ch certified by the Journalism Trust Initiative
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.